Skip to main content

Market Overview

Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price

Medivation Drops 12% After Congress Asks To Examine Xtandi Drug Price

Shares of Medivation Inc (NASDAQ: MDVN) were trading lower by more than 6 percent heading into Tuesday's market open as the company's drug pricing have come under scrutiny by the U.S. Congress.

According to ABC News, a group of U.S. lawmakers initiated a campaign to potentially lower the price of Medivation's prostate cancer drug.

Related Link: Medivaiton Offers Pivotal Phase III Trial Of Enzalutamide

Reps. Lloyd Dogget and Peter Welch, along with Senator Bernie Sanders are calling on the Department of Health and Human Services and the National Institutes of Health to cut prices for Medivation's drug, Xtandi.

The lawmakers are arguing that the price of Xtandi is 4 times larger in the U.S. compared to the rest of the world.

At time of writing, Medivation was down 12.28 percent at $36.18.

Image Credit: Public Domain


Related Articles (MDVN)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Politics Legal Movers Tech General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at